Issues surrounding the health economic evaluation of genomic technologies. - Wikidata - awgldk - TriplyDB

Issues surrounding the health economic evaluation of genomic technologies.

Issues surrounding the health economic evaluation of genomic technologies.

http://www.wikidata.org/entity/Q37541151

about

Pharmacogenomics in the clinic Economic evaluations of personalized medicine: existing challenges and current developments Personalized medicine in Europe: not yet personal enough?Personalised medicine in the UK: challenges of implementation and impact on healthcare system.Societal preferences for the return of incidental findings from clinical genomic sequencing: a discrete-choice experiment.Clinical applications of next generation sequencing in cancer: from panels, to exomes, to genomes.National Database for Autism Research (NDAR): Big Data Opportunities for Health Services Research and Health Technology Assessment.Is the ``$1000 Genome'' really $1000? Understanding the full benefits and costs of genomic sequencing.When is Genomic Testing Cost-Effective? Testing for Lynch Syndrome in Patients with Newly-Diagnosed Colorectal Cancer and Their Relatives.Evidence used in model-based economic evaluations for evaluating pharmacogenetic and pharmacogenomic tests: a systematic review protocol.A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics A Systematic Review of Health Economic Evaluations of Diagnostic Biomarkers.Economic Evaluation in Stratified Medicine: Methodological Issues and Challenges A cost analysis of a cancer genetic service model in the UK Patients' Preferences for Genomic Diagnostic Testing in Chronic Lymphocytic Leukaemia: A Discrete Choice Experiment Modeling companion diagnostics in economic evaluations of targeted oncology therapies: systematic review and methodological checklist.Can genomic medicine improve financial sustainability of health systems?HEADROOM BEYOND THE QUALITY- ADJUSTED LIFE-YEAR: THE CASE OF COMPLEX PEDIATRIC NEUROLOGY."What Goes Around Comes Around": Lessons Learned from Economic Evaluations of Personalized Medicine Applied to Digital Medicine.The cost of molecular-guided therapy in oncology: a prospective cost study alongside the MOSCATO trial.A time-and-motion approach to micro-costing of high-throughput genomic assays.Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics.Diagnosis of rare diseases under focus: impacts for Canadian patients.The economic case for precision medicine.Value-based genomics.Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions Toward health technology assessment of whole-genome sequencing diagnostic tests: challenges and solutions

P2860

Q26782786-4752490A-9407-494A-99AB-B911A9A32BE7 Q26797183-091235B4-8CB4-4AA7-A596-A517AAD82556 Q33577079-C335175A-70F3-417F-9213-76EE27142158 Q33772602-B969E8E3-4ECF-4F7A-B87C-187BE35889C3 Q35287159-E452FF23-1DE0-481D-9FE3-9EDED9E81D6A Q35749677-3D275BA8-000C-471D-9233-8C9FD33D854A Q35800876-C0979EAA-5E5F-4044-84E4-18D419F89808 Q35925229-CB45CEE8-2BA3-4665-9E58-39A3DE39000B Q36157315-4F119856-0D1D-42F9-9E5A-C5EDD27C81A9 Q36302726-A87FEF9D-4BFA-4326-B39B-C0D4EFD137FA Q36512012-837F7D92-1F63-46D4-945C-789BB1283F76 Q36541715-D36B48AD-9B5D-4CA7-9FAE-A2286B14E6C3 Q36883280-66BC1DD5-4662-4FD1-A42F-A6A000FE98F8 Q37124110-054AF29B-AA6E-44AD-9966-783E011D315A Q37410709-8992CA41-987B-4694-8719-8A7FADCF20B2 Q38241709-20F91D91-6BBF-4BBB-BE25-266BEBF4749C Q38415606-806A60D4-38E6-4B1A-975B-1127406CBE4D Q38677769-38581B5A-F1E7-4833-A5D4-0651FB2C3E83 Q38756024-282120A8-418C-4581-A2CB-3EB0B3C6EECE Q39139865-8F99F339-D6C1-41E2-98ED-D6275B011AF4 Q40417191-CB58CF40-07D1-49B7-B326-D3E2AC5073E4 Q41310328-8895AB8A-1B8D-404A-99D3-B7CB61D0F99F Q41666223-6CB33395-F92D-437F-BE2A-7E580522DCC3 Q47771558-4D11615C-41AC-4A20-8C45-8057D8F9DECA Q55217201-8AEDF0FD-E7AD-4A96-8C08-5870504C636E Q55339672-3E773D4F-D85D-449D-8A72-FCBF5433B001 Q57166342-E437A438-6515-4DCE-84CC-FBFD6EB4B872 Q57697360-1D75D1D3-511B-4303-A83A-DCB17B9C16DE

P2860

Issues surrounding the health economic evaluation of genomic technologies.

http://www.wikidata.org/entity/Q37541151

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Issues surrounding the health economic evaluation of genomic technologies.

@en

Issues surrounding the health economic evaluation of genomic technologies.

@nl

type

label

Issues surrounding the health economic evaluation of genomic technologies.

@en

Issues surrounding the health economic evaluation of genomic technologies.

@nl

prefLabel

Issues surrounding the health economic evaluation of genomic technologies.

@en

Issues surrounding the health economic evaluation of genomic technologies.

@nl

P1433

Q37541151-AE63FFF6-59FB-4FEE-804E-FF82E0863010

P1476

Q37541151-A482C34F-C660-4A54-A5FF-63064AD26C0C

P2093

Q37541151-DB29FF3E-FFF9-4B14-AAB4-A0BC5BBBB002

Q37541151-FD3DD191-6498-4E31-830A-28D45BD389C8

P2860

Q37541151-0BC60054-FEDF-49E0-8E36-B03CE51F19CB

Q37541151-0F87BDB6-6545-4B0F-8A29-109B1FB8E016

Q37541151-13215AEE-E43F-4E34-9B48-F7D6BD9DB6C9

Q37541151-142F6CD1-DC8E-4D67-8D13-95863BD67A82

Q37541151-17D9803A-810C-472E-8BC0-6124CDC937E3

Q37541151-1F53A602-F0D7-49BF-BA17-5FB044E2DF64

Q37541151-24A61762-474A-4867-882B-A45D1949F048

Q37541151-2D34BCC7-16FD-485C-9279-FF047DED5C62

Q37541151-3A1D9AB0-4E04-479A-B0BF-3DAFA36BB830

Q37541151-43882E1D-90AA-4D52-B1C4-57AA723D8AB1

P304

Q37541151-0B44C343-40F4-43B9-8F6C-72C2847ADD45

P31

Q37541151-4DC7D76B-AB2F-4259-ACAC-267E2F879FFA

P356

Q37541151-56F099C5-E9A7-4862-962C-24306CC55485

P433

Q37541151-0FB43C44-60DA-432B-A18A-98D4F5C83CEE

P478

Q37541151-70CA9AB4-969B-43DF-88CA-F628374E1DE8

P50

Q37541151-029FABFC-9532-4014-AD87-3E49C7C2FA96

P577

Q37541151-BBA1A9B8-F8BE-4884-A1AC-B4E6F963E552

P698

Q37541151-568FB3D8-94D8-4C23-9CE4-B468F700B0D4

P932

Q37541151-ACB748A3-FF82-4F64-901B-3A3FEC038700

P356

P1433

Pharmacogenomics

P1476

Issues surrounding the health economic evaluation of genomic technologies.

@en

P2093

Anna Schuh

http://www.w3.org/2001/XMLSchema#string

Sarah Wordsworth

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacogenetics in Europe: barriers and opportunities

We screen newborns, don't we?: realizing the promise of public health genomics

The impact of next-generation sequencing technology on genetics

Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research

Value for money? Array genomic hybridization for diagnostic testing for genetic causes of intellectual disability.

Challenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic value.

Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.

Points to consider in assessing and appraising predictive genetic tests.

Stakeholder perspectives on a risk-benefit framework for genetic testing.

P304

1833-1847

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/PGS.13.183

http://www.w3.org/2001/XMLSchema#string

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24236483

http://www.w3.org/2001/XMLSchema#string

P932

3909837

http://www.w3.org/2001/XMLSchema#string